Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane®) by the Pediatric Preclinical Testing Program (PPTP)

Pediatric Blood and Cancer

Volumn 62, Issue 7, 2015, Pages 1214-1221

  Houghton, Peter J ^a   Kurmasheva, Raushan T ^a   Kolb, E Anders ^b   Gorlick, Richard ^c   Maris, John M ^d,e   Wu, Jianrong ^f   Tong, Zeen ^g   Arnold, Michael A ^a,h   Chatterjee, Moumita ⁱ   Williams, Terence M ⁱ   Smith, Malcolm A ^j  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^c CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g CELGENE CORPORATION   (United States)

^h THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

^j NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

Abraxane; Developmental therapeutics; nab paclitaxel; Preclinical testing

Indexed keywords

CAVEOLIN 1; OSTEONECTIN; PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; MESSENGER RNA; NANOPARTICLE; SPARC PROTEIN, MOUSE; TUBULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG SCREENING; DRUG TOLERABILITY; ELECTROSPRAY; EVENT FREE SURVIVAL; EWING SARCOMA; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; OSTEOSARCOMA; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VOLUME OF DISTRIBUTION; ADULT; ANIMAL; CHEMISTRY; CHILD; ENZYME IMMUNOASSAY; GENETICS; HUMAN; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA, EXPERIMENTAL; SCID MOUSE; TISSUE DISTRIBUTION; TUMOR CELL CULTURE;

ADULT; ALBUMINS; ANIMALS; CAVEOLIN 1; CHILD; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, SCID; NANOPARTICLES; OSTEONECTIN; PACLITAXEL; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SARCOMA, EXPERIMENTAL; TISSUE DISTRIBUTION; TUBULIN; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929305022     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25474     Document Type: Article

References (26)

1. Desai N, Trieu V, Damascelli B, Soon-Shiong P. SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2009; 2:59-64.
2. de Leon MC, Bolla S, Greene B, Hutchinson L, Del Priore G. Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel. Gynecol Oncol Case Rep 2013; 5:70-71.
3. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. Int J Nanomed 2009; 4:99-105.
4. Hayashi RJ, Blaney S, Sullivan J, Weitman S, Vietti T, Bernstein ML. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: A pediatric oncology group study. J Pediatr Hematol Oncol 2003; 25:539-542.
5. Hurwitz CA, Strauss LC, Kepner J, Kretschmar C, Harris MB, Friedman H, Kun L, Kadota R. Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: A pediatric oncology phase II study. J Pediatr Hematol Oncol 2001; 23:277-281.
6. Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, Smith EI, London WB, Castleberry R. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: A pediatric oncology group study. J Clin Oncol 2004; 22:4119-4126.
7. Doz F, Gentet JC, Pein F, Frappaz D, Chastagner P, Moretti S, Vassal G, Arditti J, Tellingen OV, Iliadis A, Catalin J. Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: A SFOP study. Br J Cancer 2001; 84:604-610.
8. Zhang L, Marrano P, Kumar S, Leadley M, Elias E, Thorner P, Baruchel S. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. Clin Cancer Res 2013; 19:5972-5983.
9. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C, Gorlick R, Kolb EA, Zhang W, Lock R, Carol H, Tajbakhsh M, Reynolds CP, Maris JM, Courtright J, Keir ST, Friedman HS, Stopford C, Zeidner J, Wu J, et al. The Pediatric Preclinical Testing Program: Description of models and early testing results. Pediatr Blood Cancer 2007; 49:928-940.
10. Kolb EA, Gorlick R, Reynolds CP, Kang MH, Carol H, Lock R, Keir ST, Maris JM, Billups CA, Desjardins C, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer 2013; 60:1325-1332.
11. Wong H, Choo EF, Alicke B, Ding X, La H McNamara, Theil FP, Tibbitts J, Friedman LS, Hop CE, Gould SE. Antitumor activity of targeted and cytotoxic agents in murine subcutaneous tumor models correlates with clinical response. Clin Cancer Res 2012; 18:3846-3855.
12. Morton CL, Favours EG, Mercer KS, Boltz CR, Crumpton JC, Tucker C, Billups CA, Houghton PJ. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 2007; 25:285-295.
13. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ. Improved effectiveness of nanoparticle albumin-bound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 2008; 19:899-909.
14. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A, Figg WD. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008; 14:4200-4205.
15. Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL:. The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37:1590-1598.
16. Lorenz W, Reimann HJ, Schmal A, Dormann P, Schwarz B, Neugebauer E, Doenicke A. Histamine release in dogs by Cremophor E1 and its derivatives: oxethylated oleic acid is the most effective constituent. Agents and actions 1977; 7:63-67.
17. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Jr., Van Echo DA, Von Hoff DD, Leyland-Jones B. Hypersensitivity reactions from taxol. J Clin Oncol 1990; 8:1263-1268.
18. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794-7803.
19. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL, Renschler MF. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: Final results of a phase III trial. J Clin Oncol 2012; 30:2055-2062.
20. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369:1691-1703.
21. Kottschade LA, Suman VJ, Amatruda T, 3rd, McWilliams RR, Mattar BI, Nikcevich DA, Behrens R, Fitch TR, Jaslowski AJ, Markovic SN. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group Study, N057E(1). Cancer 2011; 117:1704-1710.
22. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 5:1038-1044.
23. Lage H. An overview of cancer multidrug resistance: A still unsolved problem. Cell Mol Life Sci 2008; 65:3145-3167.
24. Wagner LM, Yin H, Eaves D, Currier M, Cripe TP. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma. Pediatr Blood Cancer 2014; 61:2096-2098.
25. Viudez A, Ramirez N, Hernandez-Garcia I, Carvalho FL, Vera R, Hidalgo M. Nab-paclitaxel: A flattering facelift. Crit Rev Oncol Hematol 2014; 92:166-180.
26. Peterson JK, Tucker C, Favours E, Cheshire PJ, Creech J, Billups CA, Smykla R, Lee FY, Houghton PJ. In vivo evaluation of ixabepilone (BMS 2475 50), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res 2005; 11:6950-6958.